Septest.
Rapid infection testing at the point of need.
In the Spotlight
Septest shortlisted for Medilink Startup Award.
Septest has been shortlisted in the startup category at the Medilink Healthcare Business Awards 2024.
This category highlights the efforts of newly established companies in the healthcare sector that show a promising future.
Septest wins the TBAT Innovation Challenge.
Septest has won the TBAT innovation challenge. Septest not only secured the judges vote but also won the audience winner vote.
Co-founder Kelly pitched at the packed showcase event alongside the nine other finalists to claim the top prize package provided by TBAT and its industry partners worth over £50,000.
Septest Completes Herts Healthcare Accelerator.
Septest has completed the 2023 hearts healthcare accelerator.
The programme provided access to a range of experts from across various fields including life sciences, technology, design, business, and law to enable the development of innovations and early stage research.
About Us
At Septest, we are dedicated to transforming the diagnostic pathway for infective and non-infective critical illness, such as SIRS and sepsis. Our innovative approach ensures early detection and more accurate treatment selection, improving outcomes for both patients and healthcare systems.
Founded by a sepsis survivor and diagnostic specialist, Septest has partnered with prominent sepsis experts and global organisations to produce a range of breakthrough point-of-need tests that can be implemented in any setting, worldwide.
Spotlight on Sepsis
Sepsis is a life-threatening illness caused by the body's response to an infection, resulting in systemic inflammation and organ dysfunction. It can affect anybody, from infants to the elderly, and progresses rapidly if not diagnosed and treated promptly.
Recognised as a global health crisis, sepsis affects an estimated 48.9 million people annually resulting in over 11 million deaths worldwide. In addition to the human toll, sepsis has a significant economic impact, with healthcare costs estimated to be in the billions of dollars every year.
Diagnostic Need
Early detection of infection and inflammatory response is key in improving outcomes, especially in sepsis, with every hour delay to treatment increasing the risk of death by 8-10%. Despite this urgency, current diagnostic methods are often time-consuming, expensive, and unavailable at the point-of-need. Septest's rapid tests intend to bridge this gap by providing simple, low-cost solutions that integrate seamlessly into existing healthcare settings.
Antimicrobial Resistance
The overuse of antibiotics in cases of non-bacterial infections has contributed to the rise of antimicrobial resistance (AMR), posing a significant challenge to infection management. This not only puts a strain on healthcare budgets, but also complicates the treatment of conditions like sepsis. Septest aims to tackle AMR by providing healthcare professionals with tools for accurate diagnosis of infections, ensuring antimicrobials are prescribed only when necessary.
Beyond Sepsis
Septest's diagnostic tests are designed to detect a broad range of infection types and monitor inflammatory response. By offering such comprehensive diagnostic capabilities, Septest has the potential to improve patient outcomes across a vast range of diverse conditions, such as COVID, pneumonia, TB, autoimmune diseases and other chronic inflammatory disorders.
Diagnostic Integration
Hospital Settings
Septest's diagnostic tests have been designed to confirm emergency treatment options following initial clinical assessment.
General Practice
Septest's diagnostic solutions are well suited for use in GP practices to rapidly rule out viruses and other types of infection.
Community Setting
All Septest diagnostic tests may be performed by community health care providers such as pharmacists and at local healthcare clinics.
Our Commitment
We are determined to see our technology in the hands of frontline healthcare workers.
Our ultra-accessible point-of-need tests have been specifically designed to reduce barriers to diagnostic access, especially in LMIC's.
By implementing our range of diagnostic solutions, we believe we can reduce delays to diagnosis, saving countless lives around the world.
Contact Us
For partnership opportunities, or to learn more about our revolutionary tests, please contact us using the form below.
Sepsis Charity Information
Further information regarding sepsis and available support can be found by visiting the following registered sepsis charities.
© 2024 Septest Limited. All rights reserved.
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. Septest's range of tests are currently in development and not yet available.
We need your consent to load the translations
We use a third-party service to translate the website content that may collect data about your activity. Please review the details in the privacy policy and accept the service to view the translations.